In April, McDermott was pleased to once again host our annual European Health & Life Sciences Symposium in Paris. Welcoming a crowd of more than 300 innovators, investors, business leaders and advisers from across the...more
5/13/2025
/ Acquisitions ,
Biotechnology ,
EU ,
Financing ,
Investment ,
Investors ,
Life Sciences ,
Mergers ,
Pharmaceutical Industry ,
Private Equity ,
Venture Capital
In April 2025, we were proud to host the annual European Health & Life Sciences Symposium at the Shangri-La hotel in Paris. Attended by some 300 delegates from across the industry, participants including investors,...more
5/5/2025
/ Artificial Intelligence ,
Biologics ,
Biotechnology ,
Clinical Trials ,
Healthcare ,
Healthcare Reform ,
Innovative Technology ,
Investment ,
Investors ,
Life Sciences ,
Pharmaceutical Industry ,
Regulatory Requirements ,
Technology Sector ,
Venture Capital
RUSSIA RESPONDS TO WESTERN SANCTIONS WITH PATENT RETALIATION -
On March 6, 2022, the Russian government retaliated against the West’s imposition of sanctions by issuing a decree permitting patented innovations to be used...more
6/27/2022
/ Appeals ,
Biotechnology ,
Cosmetics ,
Dietary Supplements ,
EU ,
France ,
Intellectual Property Protection ,
Medical Devices ,
Patent Litigation ,
Patent Validity ,
Patents ,
Pharmaceutical Industry ,
Russia ,
Sanctions ,
Trademark Litigation ,
Trademarks
In the second installment of McDermott’s webinar series, HPE Europe 2020: What are the Life Science Transaction Trends in the Wake of the Sanitary Crisis?, moderator and McDermott partner Emmanuelle Trombe and industry...more